B+
Bull case
25%
Probability
Target price
$3.20
+65.8% vs current
XCUR
ExicureCNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-21
AI scenario view
RankAlpha Sentiment CodexPost-earnings T+3Most likely
B
Base case
45%
Probability
Target price
$1.80
-6.7% vs current
B-
Bear case
30%
Probability
Target price
$0.80
-58.5% vs current
AI sentiment snapshot
Latest data as of 2026-06-30
Recent news sentiment (30D)
-0.4
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Sentiment proxy
+43.1
Score
AI commentary
This remains a cautious monitoring-style memo, not a conviction long. The scheduled earnings follow-up pointed to June 25, 2026, but the main company-source operating evidence available by June 30, 2026 is the Form 10-Q filed on May 29, 2026 and the June 1, 2026 8-K confirming the delayed filing was cured [#SEC-10Q-2026-05-29][#8-K-2026-06-01]. No trustworthy post-print analyst target-reset set was available, and immediate market-reaction evidence was not reliably confirmed from the packet. With low coverage, distressed liquidity, and loose peers, the negative deterministic prior still dominates despite strong primary-source evidence quality.
RankAlpha Sentiment Codex - 2026-06-30
Open post-earnings memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-06-30eventPlanned Q2 2026 GPCR milestone share payment can confirm program continuation but adds dilution sensitivityHigh impact
The March 31, 2026 Form 10-Q says GPCR USA completed its Phase 2 trial in January 2026 and that Exicure intends to make a $1.0 million milestone payment to GPCR in the second quarter of 2026 in common stock; that would support continued commitment to GPC-100 but keeps dilution in focus [#SEC-10Q-2026-05-29].
2026-07-31catalystQ1 filing kept financing pressure front-and-centerHigh impact
The clearest post-print company source is the Form 10-Q filed on May 29, 2026, which showed cash and cash equivalents fell to $2.6 million from $3.7 million at December 31, 2025, stockholders’ equity fell to about $2.1 million, and management said current liquidity may not be sufficient for the next 12 months and that failure to raise capital could lead to bankruptcy protection or cessation of operations [#SEC-10Q-2026-05-29].
2026-12-31catalystStrategic alternative or partnering around the GPCR asset remains the only credible rerating pathHigh impact
Company filings still frame Exicure as a strategic-alternatives story with limited standalone runway, while the GPCR asset is the only visible operating program with potential partnering value; a concrete licensing, funding, or development transaction would matter more than routine corporate updates, but visibility remains weak [#SEC-10Q-2026-05-29][#SEC-8K-2026-03-25].
Recommendation
N/A
No formal recommendation provided.
As of 2026-06-30 • Updated nightlySource: Internal modelMethodology